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Abstract: It is not clear how the profile of immune cells in peripheral blood differs between patients
with clinically isolated syndrome (CIS) and healthy controls (HC). This study aimed to identify a
CIS peripheral blood signature that may provide clues for potential immunomodulatory approaches
early in disease. Peripheral blood mononuclear cells (PBMCs) were collected from 18 people with
CIS, 19 HC and 13 individuals with other demyelinating conditions (ODC) including multiple
sclerosis (MS). Individuals with CIS separated into two groups, namely those with early (≤14 days
post-diagnostic magnetic resonance imaging (MRI); n = 6) and late (≥27 days; n = 12) blood sampling.
Transitional B cells were increased in the blood of CIS patients independently of when blood was
taken. However, there were two time-dependent effects found in the late CIS group relative to
HC, including decreased CD56bright NK cells, which correlated significantly with time since MRI,
and increased CD141+ myeloid dendritic cell (mDC2) frequencies. Higher CD1c+ B cells and lower
non-classical monocyte frequencies were characteristic of more recent demyelinating disease activity
(ODC and early CIS). Analysing cell populations by time since symptoms (subjective) and diagnostic
MRI (objective) may contribute to understanding CIS.
Keywords: multiple sclerosis; clinically isolated syndrome; immunology; pathology; B cells; NK cells
1. Introduction
Clinically isolated syndrome (CIS) is often the first indication of multiple sclerosis (MS),
though prediction of disease course in individuals with CIS is challenging, with few markers to predict
conversion to MS [1]. When progression to MS does occur, the episode of CIS in that individual might
be considered the first episode of relapsing-remitting MS (RRMS), although definitive clinical diagnosis
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does not occur until after the second demyelinating event. In RRMS, peripheral blood cells could reflect
either the acute inflammation that causes damage to the central nervous system (CNS), or between
attacks, they may signal the reparative activity occurring that temporarily resolves the demyelination
and symptoms, driven by leukocytes with suppressive activities. Despite this, the phenotypes of
peripheral blood cells observed between magnetic resonance imaging (MRI)-diagnosed attacks are not
well understood, and their relationships with ongoing disease-specific processes are unclear.
Bi-directional movement of leukocytes is observed between the CNS and the cervical lymph
nodes in MS [2], which may explain why MS therapies directed peripherally can reduce CNS
inflammation. An investigation of circulating cells at the time of clinically-evident disease activity
may therefore give clues to disease pathogenesis as well as provide insight into potential cellular
targets for treatment to prevent future demyelinating events. In this study, peripheral blood samples
from individuals with CIS (recruited at baseline into an interventional trial with narrowband UV-B
phototherapy [3]) were analysed and compared with peripheral blood samples taken from healthy
controls. In addition, blood samples taken from people with other acute demyelinating conditions
(and recent clinically-evident disease) were included to provide evidence as to whether changes
observed were generally associated with MRI demyelination or were specific to CIS at high risk of
conversion to MS. We sought to define immunological characteristics specific to cells from individuals
with CIS that would, in turn, provide evidence about the pathogenesis of early MS, before definitive
diagnosis based on a second demyelinating event. We found that when time since MRI diagnosis and
clinical presentation was accounted for in the CIS group, changes to cell subset frequencies in sampled
blood emerged that differentiated those with recent diagnosis from those with a delay since diagnosis.
These findings indicate the importance of considering time since the clinical event when conducting
immunological assessments in CIS.
2. Results
2.1. Study Participant Demographics
Participants in the healthy control (HC), CIS and other demyelinating conditions (ODC) groups
were not significantly different in age or sex (Table 1). However, for many CIS patients compared to
those with ODC, a significantly longer time had elapsed between onset of symptoms and diagnostic
MRI, and between diagnostic MRI and blood donation. Despite this trend, six people with CIS had
significantly shorter periods between symptom onset, diagnostic MRI and blood sampling than other
CIS patients, as shown in Table 1. As the time of symptom onset can be subjectively recalled, the date
of diagnostic MRI provided the most objective measure for time since start of disease and was used in
subsequent analyses.
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Post-MRI) (n = 12)
p Value
Age (median (range)) 41 (22, 61) 34 (18, 75) 35 (29, 49) 42 (23, 54) 0.444
Sex (F), n (%) 12 (63%) 8 (62%) 3 (50%) 9 (75%) 0.758
Days from MRI diagnosis
to blood sampling
(median (range))
n/a 4 (−2, 20) a 4 (−7, 14) b 38 (27, 98) a,b <0.001
Days from reported
symptom onset to blood
sampling (median (range))
n/a 10 (4, 27) a 13 (6, 31) b 65 (39, 137) a,b <0.001
Days from symptom onset
to diagnostic MRI
(median (range))
n/a 6 (0, 27) a 11.5 (7,17) 26 (2, 101) a 0.004
Legend: n/a = not applicable. Letter superscripts indicate groups that were significantly different from one another
in post-tests. Bolded formatting for p values indicate values that were considered statistically significant.
2.2. Peripheral Blood Mononuculear Cell (PBMC) Subset Frequencies in Different Clinical Groups
To investigate whether we could find a CIS-specific signature, we initially compared the frequency
of peripheral blood mononuclear cell (PBMC) subsets in all people with CIS to those with ODC and
HC (Table A1). The ODC group had its own signature, namely increased CD1c+ B cells and decreased
non-classical monocytes as a proportion of all PBMC. In blood samples from people with CIS compared
to HC, there were significantly increased frequencies of transitional B cells (IgD+CD27−CD24hiCD38hi
B cells) as a percent of B cells, and CD141+ DCs as a percent of DCs. However, as demonstrated in
Table 1, the CIS group was heterogeneous in time since symptom onset and in relation to diagnostic
MRI. We could not determine whether these results (changes in transitional B cells and CD141+ DCs)
were a signature specific to CIS, or were influenced by the variable of time between MRI and blood
draw, and so this variable was included in all further analyses. The CIS participants clearly separated
into two groups according to the time between diagnostic MRI and blood sampling (Table 1). In one
group, the blood sample was taken within 14 days (n = 6) of diagnostic MRI (hereafter referred to
as “early CIS”), while in the other group, blood was collected ≥27 days after their diagnostic MRI
(hereafter referred to as “late CIS”; n = 12). The median times since reported symptom onset at the
time of blood sampling for the two groups were 13 and 65 days, respectively. For the ODC group,
all blood samples were collected within 20 days of diagnostic MRI.
There were no detectable differences between the four groups (HC, ODC, and two CIS groups) in
total monocytes, total DCs, total B cells or total NK cells as a frequency of PBMCs (Table A2). However,
when investigating subsets of these cell types, alterations in several NK, B cell and DC subsets in
samples from the late CIS individuals were observed, shown in Figure 1 and Table A2. In particular,
the late CIS group had significantly lower frequencies of CD56brightCD16loNK cells (% NK cells;
Figure 1) compared with early CIS or HC patients.
Cell subsets that were significantly different between HC and either of the two CIS sampling
groups in the previous analyses (Figure 1) were further investigated in the CIS participants in relation
to time since diagnostic MRI, considered as a continuous variable. There was no correlation between
the time since diagnostic MRI and the frequencies of transitional B cells, CD141+ DCs or non-classical
monocytes (Figure 2). However, a significant negative or positive correlation with days since MRI was
observed for CD56bright NK cells, CD56dim NK cells, and CD1c+ B cells in the samples from those
with CIS.
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Figure 1. Cell frequencies significantly different between healthy controls (HC), other demyelinating 
conditions (ODC), early cliniclaly isolated syndrome (CIS) and late CIS. (A) Cell types that were 
significantly altered compared with HC in the ODC group; (B) Cell types that were significantly 
increased from HC in the late CIS group; (C) Cell types that were significantly decreased from HC or 
early CIS in the late CIS group. Individual data are shown in addition to median and interquartile range, 
indicated by the bar graph and error bars. Significant differences between groups in Kruskal Wallis 
tests with Bonferroni corrected post-tests are indicated by lines with asterisks. CD56dimCD16hi NK 









































































































Figure 1. Cell frequencies significantly different between healthy controls (HC), other demyelinating
conditions (ODC), early cliniclaly isolated syndrome (CIS) and late CIS. (A) Cell types that were
significantly altered compared with HC in the ODC group; (B) Cell types that were significantly
increased from HC in the late CIS group; (C) Cell types that were significantly decreased from HC or
early CIS in the late CIS group. Individual data are shown in addition to median and interquartile range,
indicated by the bar graph and error bars. Significant differences between groups in Kruskal Wallis
tests with Bonferroni corrected post-tests are indicated by lines with asterisks. CD56dimCD16hi NK
cell frequencies were significantly different in Kruskal Wallis test, but the post-test was not significant
between groups.
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Figure 2. Correlations between time since diagnostic magnetic resonance imaging (MRI) and cell 
subsets in CIS previously shown to be significantly different to HC in Kruskal Wallis tests. (A) Cell 
types that were significantly altered compared with HC in ODC; (B) Cell types that were significantly 
increased from HC in the late CIS group; (C) Cell types that were significantly decreased from HC or 
early CIS in the late CIS group. Correlations are shown by ρ and p values from Spearman correlation 
tests. 
3. Discussion 
This study aimed to identify a CIS-specific PBMC signature that provided clues about 
dysfunctional immune cells early in the RRMS disease course. People with CIS compared with HC 
had a peripheral blood signature characterised by significantly increased transitional B cells and 
CD141+ DCs as a frequency of B cells and DCs, respectively. These changes were not correlated with 
time since diagnostic MRI, nor were they associated with ODC. However, time-dependent changes 
in CD1c+ B cells and CD56brightCD16lo NK cell subsets in blood from CIS participants were 
detected. These data suggest that the timing of the blood sample with reference to symptom onset 
and diagnostic MRI in the clinical course of CIS is an important factor to consider when interpreting 
findings for CIS. Potentially, the increases in CD1c+ B cells and CD56bright NK cells we observed 
after diagnosis of CIS would have prognostic value if these cell frequencies increase proximal to the 
development of new demyelinating lesions. 
Figure 2. orrelations bet een ti e since diagnostic agnetic resonance i aging ( I) and cell
s bsets i IS revio sly s o to be sig ifica tly iffere t to i r skal allis tests. ( ) ell
t es t at ere si ifica tl altere c are it i ; ( ) ell ty es that ere significa tl
i cr s from HC in the late CIS group; (C) Cell types that were significantly decreased from
HC or early CIS in the late CIS g oup. Correlations are shown by ρ and p values from Spearma
correlation tests.
3. Discussion
This study ai ed to identify a CIS-specific PB C signature that provided clues about
dysfunctional i une cells early in the RRMS disease course. People with CIS compared with
HC had a peripheral blood signature characterised by significantly increased transitional B cells and
CD141+ DCs as a frequency of B cells and DCs, respectively. These changes were not correlated with
time since diagnostic RI, nor were they associated with ODC. However, time-dependent changes in
CD1c+ B cells and CD56brightCD16lo NK cell subsets in blood from CIS participants were detected.
These data suggest that the timing of the blood sample with reference to symptom onset and diagnostic
MRI in the clinical course of CIS is an important factor to consider when interpreting findings for CIS.
Potentially, the increases in CD1c+ B cells and CD56bright NK cells we observed after diagnosis of CIS
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would have prognostic value if these cell frequencies increase proximal to the development of new
demyelinating lesions.
Peripheral blood collected in late CIS participants had significantly decreased frequencies of
CD56bright NK cells compared with HC, suggesting that there are dynamic changes in this subset in
blood during the course of an episode of CIS that may be related to CNS changes. This cell signature
was not seen when all CIS patients were initially combined as a single group and compared with
HC or ODC. Blood samples collected in the early CIS group displayed a trend toward increased
frequencies of these cells compared with HC and displayed significant increases compared with
blood cells from late CIS. This finding was reinforced by the negative correlation between CD56bright
NK cell frequencies and time since MRI across all CIS blood samples. Our results support previous
findings that peripheral blood from people with MS has fewer CD56bright NK cells than HC [4].
Other findings have been reported; CD56bright NK cells were increased in blood from people with
RRMS with no disease-associated MRI changes over 2.4 years [5]. CD56 bright NK cells can have
multiple functions, including production of cytokines such as IFN-γ, IL-10 and TNF-β, as well as
cytotoxic and regulatory activities in T cell responses [5,6]. CD56bright NK cells are reported to be
more concentrated in the cerebrospinal fluid (CSF) of people with MS compared with blood from
the same donor [7] with defective capacity to inhibit autologous T cells [8]. These cells respond to
CCL19 and CCL21 chemokine gradients via CCR7 [9]; chemokines that are upregulated in active
brain lesions in chronic relapsing experimental autoimmune encephalomyelitis (EAE) and MS [10,11].
Differences observed in CD56bright NK cell frequencies in this study associated with time since the
clinical event in CIS could therefore reflect the immunological activity of brain lesions at the time
of blood sampling. We can only speculate whether the situation in the CNS mimics the peripheral
blood. However, our observations suggest that migration of CD56bright NK cells through peripheral
blood from bone marrow or lymphoid tissue to the site of demyelination occurs early in CIS, and then
peripheral blood frequencies of these cells may normalise as the CNS inflammation resolves. Overall,
our data support the hypothesis that NK cells are important in the immune changes occurring in CIS,
even prior to development of clinically confirmed MS.
Transitional B cells were significantly increased in frequency as a percent of B cells in blood
sampled from people with CIS compared with HC. These (and other B cells) respond to the
cytokine B cell activating factor of the TNF family (BAFF), which stimulates their proliferation and
differentiation [12]. Overexpression of BAFF has been demonstrated in MS lesions; however, atacicept,
which was developed to target BAFF for this reason, unexpectedly worsened disease in a human
trial [13]. Conversely, a recent study of several current immunomodulatory treatments showed that
following administration of IFN-β and fingolimod, an increase in transitional B cells was observed in
peripheral blood, associated with increased BAFF levels in plasma [14]. Together, these data suggest
that the increased transitional B cells observed in CIS could represent both pathogenic and regulatory
subpopulations. That is, either pathogenic transitional B cells respond to the increased BAFF signalling
from the CNS and contribute to inflammation, or increased regulatory transitional B cell output from
the bone marrow reflects a suppressive response to the inflammation, or both. Since transitional B
cells can contain B regulatory cells (Bregs) [15], more markers are needed to determine whether these
expanded populations of “transitional” B cells in CIS contain more than one functional population
(e.g., identified by IL-10 or IgG4 production), since this could not be determined from our data.
Two cell subsets differentiated ODC from the early CIS group. The first cell subset was the
CD56bright NK cell population, which was not different in ODC compared with HC despite differences
in frequency in the CIS population. The second differentiating cell type was the non-classical monocyte
(CD16+); this was significantly decreased in ODC compared with HC but not in CIS. This finding is
supported by recent publications analysing CD16+ monocytes and their gene expression in peripheral
blood and the CSF of people with MS [16,17]. CD16+ monocytes from MS patients tend to have
increased surface expression of activation markers and respond more robustly with inflammatory
cytokine production to in vitro stimulation compared with cells from healthy controls [18,19].
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Unless the similarity between HC and CIS is an effect of the small sample size of our early CIS
group, these findings suggest that CIS is immunologically distinct from ODC (including MS) in their
capacity for immune cells to stabilise to “normal” levels after a demyelinating event in the CNS.
Potentially, the decrease of CD16+ monocytes seen in ODC is a result of the changes that occur with
repeated demyelination events in the MS group, but this could not be determined in our study.
We have shown, for the first time, that patients who gave blood at times closer to their symptom
onset and diagnostic MRI had higher levels of CD1c+ B cells in their peripheral blood compared with
HC. This was not apparent for people with late CIS. CD1c on B cells is responsible for presenting
lipid antigens to T cells, including self-antigens, and the responding self-reactive T cells contribute to
autoimmune diseases such as rheumatoid arthritis [20]. Structural chemistry indicates that the lipids
likely to bind to CD1c include cholesterol esters, potentially including MS-relevant molecules such as
sphingolipids [20]. Therefore, the increased frequency of CD1c+ B cells may indicate that they have a
pathogenic role; in the context of an open blood brain barrier in acute demyelination, the ability of
B cells to take up neural antigens and act as antigen-presenting cells to T cells to induce anti-myelin
responses may contribute to progression of disease. In this study, inclusion of time since diagnostic
MRI as a variable in people with ODC and CIS allowed confirmation of changes that may occur closer
to the clinical event. The benefit of this approach was clearly demonstrated in reference to the CD1c+ B
cell population, a cell that may present a diagnostic marker of CNS demyelination that can be related
to MRI findings.
Given that immune-modulating therapies for demyelinating diseases are often delivered
peripherally with beneficial CNS effects, as well as the bi-directional movement of cells between the
CNS and periphery, the profile of blood cells may reflect the disease course in the CNS. Although ideally
one would biopsy the demyelinating lesion or sample the CSF in patients with demyelinating disease,
these are far more invasive procedures than blood collection, with CSF having the limitation of
lower cell counts [21]. Consequently, we chose to study more accessible peripheral blood, which is
much more frequently accessible with abundant leukocytes for characterisation. While it has been
reported that some cell frequencies correlate between the CSF and blood, other cells frequencies may
be independent in each compartment [7]. Despite this limitation, the current study shows the relevance
of time-dependent peripheral blood changes in CIS, and the importance of careful interpretation of
cell changes in peripheral blood with reference to those of healthy controls. Our findings suggested
that at blood sampling times closer to the time of clinical presentation and diagnostic MRI, alterations
to the cell frequency profile compared with HC may reflect responses aligned with the demyelinating
event in the CNS. However, at later sampling time points, cell profiles may reflect ongoing pathogenic
and/or reparative processes. In this study, the two CIS groups separated easily according to time
between diagnostic MRI and blood sampling. The smaller group of six early CIS patients was similar
to the ODC participants in time from blood draw to diagnostic MRI and symptom onset, and while
these patients had similarities in many cell types, they could be distinguished from ODC based on
frequencies of some innate immune cells (NK cells and non-classical monocytes). Given that all ODC
samples were collected early in the disease course, it was not possible to assess the effect of time to
sampling from MRI in ODC, and this could be the subject of future investigations.
4. Materials and Methods
4.1. Study Participants
Individuals presenting with a first demyelinating event at <120 days post-MRI diagnosis of CIS
were included (n = 18). In addition, 19 HC, and 13 people with other demyelinating conditions (ODC;
seven with acute optic neuritis, one with clinically isolated myelitis, all with an isolated appropriate
MRI abnormality, and five with acute relapse of definite MS according to the current consensus
McDonald criteria [22]) were recruited. None of the study participants had received disease-modifying
treatments (including steroids) for at least one month prior to blood sampling. Pregnant women
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were excluded. CIS was diagnosed from demyelination on MRI according to PatyA or PatyB criteria,
whereas those with optic neuritis and clinically isolated myelitis included in ODC had MRI changes
consistent with the presenting demyelinating lesion but not satisfying PatyA or PatyB criteria.
Clinical data including age, sex, reported date of symptom onset, and MRI date were collected for
all participants. This study was approved by the University of Western Australia Human Research
Ethics Committee (2014-02-083, approved 22 April 2014) and Sir Charles Gairdner Hospital Human
Research Ethics Committee (2006-073, approved 27 September 2006), and all participants provided
written consent before any study procedures were performed.
4.2. Flow Cytometry
PBMCs were isolated from fresh heparinized blood collected in lithium heparin vacutainers (BD)
using a Lymphoprep (Axis-Shield, Oslo, Norway) density separation gradient. Freshly isolated PBMCs
were stained and examined for a range of cell types using antibodies to surface markers characteristic
of B, NK, monocyte, and dendritic cell (DC) subsets.
PBMCs were stained by incubating 106 cells at 4 ◦C in 100 µL of phosphate buffered saline
(PBS) with the following mouse anti-human antibodies: FITC conjugated anti-CD45 (clone HI30),
PE conjugated anti-CD19 (HIB19), PE-CF594 conjugated anti-CD24 (ML5), PE-Cy7 conjugated anti-IgD
(IA6-2), APC-H7 conjugated anti-CD20 (2H7), BV421 conjugated anti-CD38 (HIT2), BV510 conjugated
anti-CD27 (L128), FITC conjugated anti-CD303 (AC144), PE conjugated anti-CD1c (AD5-8E7),
PE-CF594 conjugated anti-CD56 (B159), PerCP-Cy5.5 conjugated anti-CD19 (HIB19), PerCP-Cy5.5
conjugated anti-CD20 (2H7), PE-Cy7 conjugated anti-cD14 (M5E2), Alexa Fluor 700 conjugated
anti-CD3 (UCHT1), APC-H7 conjugated anti-CD16 (3G8), BV421 conjugated anti-CD57 (NK-1),
and BV711 conjugated anti-CD141 (1A4). All antibodies were purchased from BD (North Ryde,
NSW, Australia), except for anti-CD303 and anti-CD1c, which were purchased from Miltenyi Biotech
(Macquarie Park, NSW, Australia).
After incubation, cells were washed with sterile PBS before resuspension in PBS for analysis.
Data were acquired using the BD LSRFortessa flow cytometer instrument in combination with
FACSDiva software (Version 8.0.1, BD Biosciences, Franklin Lakes, NJ, USA) and analysed using
FlowJo v10 (Tree Star, Ashland, OR, USA). Approximately 200,000–500,000 events were acquired for
each sample.
The B cell gating was performed as shown in Figure 3, and the monocytes, NK cells and DCs
gated as shown in Figure 4 below.
4.3. Statistical Analyses
Continuous data were tested for normality using a Shapiro-Wilk test. Non-parametric correlation
was described between continuous variables including time since MRI and flow cytometry frequency
data using Spearman’s rho (ρ). The differences between the HC, CIS and ODC groups were tested
using a Kruskal-Wallis test using Bonferroni’s correction in the post-test (where appropriate) for
continuous variables, and a Chi-squared test for categorical variables including sex. Cells identified in
flow cytometry were analysed and presented as a frequency of PBMCs and as a frequency of B cells,
monocytes, dendritic cells or NK cells, where relevant. The alpha value for all tests was set to 0.05.
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Figure 3. The gating strategy applied to peripheral blood mononuclear cells (PBMCs) analysed for B 
cell subsets. (A) PBMCs were selected according to forward scatter (FSC)/side scatter (SSC) profile; 
(B) Leukocytes were identified based on CD45 expression; (C) CD19+CD20− B cells were separated 
from double positive and CD19− cells; (D) CD19+CD20− B cells that were positive for CD27 and CD38 
were selected as probable antibody secreting cells; (E) Identification of antibody secreting cells (ASC) 
was confirmed from negative expression of CD24 and IgD; (F) Double positive B cells identified in C 
were separated into switched memory, non-switched memory and double negative memory B cells 
using CD27 and IgD expression; (G) IgD+CD27− cells in F were separated into naïve B cells (all 
CD38−/low), CD24hi naïve and transitional B cells using CD38 and CD24 expression. 
Figure 3. The gating strategy applied to peripheral bl od mononuclear ce ls (PBMCs) analysed for B
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(ASC) was confirmed from negative expression of CD24 and Ig ; (F) Double positive B cells identified
in C were separated into switched memory, non-switched memory and double negative memory B
cells using CD27 and IgD expression; (G) IgD+CD27− cells in F were separated into naïve B cells (all
CD38−/low), CD24hi naïve and transitional B cells using CD38 and CD24 expression.
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Figure 4. The gating strategy applied to PBMCs analysed for monocytes, NK cells and DCs. (A) 
PBMCs were selected according to the forward scatter (FSC)/side scatter (SSC) profile; (B) NK cells, 
NKT and γδ-T cells were separated from CD56− cells, and from one another according to CD3 
staining; (C) NK cells gated in B were separated into CD56brightCD16lo, CD56brightCD16int and 
CD56dim cells, according to CD16 and CD56 staining; (D) CD56dim NK cells were further separated 
into CD57+ or CD57− according to CD57 expression; (E) B cells were separated from non-B cells in the 
non-NK, NKT or γδ-T cell CD56- category identified in B. B cells were also divided into CD1c+ or 
CD1c− populations; (F) Non-B cells identified in E were divided into CD141+ myeloid DCs (mDC2), 
CD303+ plasmacytoid DCs (pDCs), or other cells. (G) Cells negative for CD141 and CD303 staining 
in F were separated based on CD16 and CD14 expression into classical (CD14hiCD16−), intermediate 
(CD14+CD16+) and non-classical (CD14loCD16+) monocytes (reference [23]), as well as CD14−CD16− 
cell types; (H) The CD14−CD16− cells identified in G were gated on CD1c+ to identify CD1c+myeloid 
DCs (mDC1). 
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It is clear from our analytical approach that while it is common to report whether blood studied 
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were selected according to the forward scatter (FSC)/side scatter (SSC) profile; (B) NK cells, NKT
and γδ-T cells were separated from CD56− cells, and from one another according to CD3 staining;
(C) NK cells gated in B were separated into CD56brightCD16lo, CD56brightCD16int and CD56dim cells,
according to CD16 and CD56 staining; (D) CD56dim NK cells were further separated into CD57+ or
CD57− according to CD57 expression; (E) B cells were separated from non-B cells in the non-NK, NKT
or γδ-T cell CD56- category identified in B. B cells were also divided into CD1c+ or CD1c− populations;
(F) Non-B cells identified in E were divided into CD141+ myeloid DCs (mDC2), CD303+ plasmacytoid
DCs (pDCs), or other cells. (G) Cells negative for CD141 and CD303 staining in F were separated
based on CD16 and CD14 expre sion into classical (CD14hiCD16−), intermediat (CD14+CD16+) and
non-classical (CD14loCD16+) mono ytes (refer nce [23]), as well as D14−CD16− cell types; (H) The
CD14− D16− cells identified in G were gated on CD1c+ to identify CD1c+myeloid DCs (mDC1).
5. Conclusions
It is clear from our analytical approach that while it is common to report whether blood studied
was sampled within one month of immunomodulatory therapies, it is equally important to state when
blood was taken relative to the time of clinical presentation and diagnosis due to the dynamic cell
activities observed in CIS. Prognostic markers, e sily obtained from peripheral blood and ass ssed
using flow cytom try, wou d be valuable to guide clinical care decisions. Therefore, the association
between cell frequencies at the time of this first symptomatic demyelinating event and clinical and
MRI outcomes at later time points will be the subject of future investigations upon trial completion.
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Abbreviations
APC Allophycocyanin
BAFF B cell activating factor
BV Brilliant Violet
CCL19 Chemokine ligand 19
CCL21 Chemokine ligand 21
CCR7 Chemokine receptor 7
CIS Clinically isolated syndrome
CNS Central nervous system
CSF Cerebrospinal fluid
DC Dendritic cell




IgG4 Immunoglobulin G subclass 4
IL-10 Interleukin 10
ODC Other demyelinating conditions
PBMC Peripheral blood mononuclear cell
PE Phycoerythrin
PBS Phosphate buffered saline
MRI Magnetic resonance imaging
MS Multiple sclerosis
NK Natural killer
RRMS Relapsing-remitting multiple sclerosis
TNF-β Tumor necrosis factor beta
UV-B Ultraviolet B
Appendix A
Table A1. Frequencies of cell subsets in healthy controls (HC), other demyelinating conditions (ODC),
and CIS analysed by flow cytometry according to the percentage of total PBMCs, and where relevant,
percentage of total B cells, monocytes, NK cells or DCs.
Cell Type HC (n = 19) ODC (n = 13) CIS (n = 18) p Value
Median IQR Median IQR Median IQR
%PBMC
γδ−T cells 0.43 0.28–0.76 0.61 0.23–1 0.38 0.29–0.58 0.891
NKT cells 2.21 1.33–4.1 2.32 1.38–2.72 1.92 1.14–2.62 0.519
Total B cells 8.55 5.71–10.56 7.86 7.06–10.89 7.55 5.41–9.33 0.476
Total DCs 0.86 0.68–1.09 0.74 0.51–0.87 0.92 0.77–1.05 0.165
Total monocytes 14.74 10.87–15.71 9.01 5.33–18.1 15.90 11.08–17.95 0.093
Total NKs 9.59 6.44–11.46 7.72 4.94–9.79 9.66 7.68–11.39 0.374
B cells (% PBMC)
Antibody secreting cells 0.04 0.02–0.06 0.06 0.03–0.13 0.04 0.03–0.12 0.479
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Table A1. Cont.
Cell Type HC (n = 19) ODC (n = 13) CIS (n = 18) p Value
Median IQR Median IQR Median IQR
CD1c− B cells 4.43 3.03–6.48 4.26 3.82–5.85 4.34 2.89–5.45 0.687
CD1c+ B cells 2.77 a 2.37–3.68 5.11 a,b 4.06–6.56 2.98 b 2.44–4 0.003
CD24hi CD38- B cells 0.35 0.28–0.5 0.50 0.23–0.55 0.47 0.44–0.67 0.344
CD27+ B cells 3.00 2.06–3.32 2.37 1.67–3.82 2.11 2–3.12 0.628
Double negative memory B cells 0.24 0.15–0.43 0.33 0.23–0.39 0.28 0.21–0.49 0.41
Naïve B cells 4.49 2.58–6.21 4.94 3.81–5.33 4.14 2.57–6.41 0.745
Non-switched memory B cells 1.39 1.06–2.01 0.95 0.5–1.85 1.18 0.94–1.48 0.263
Switched memory B cells 1.08 0.75–1.62 1.34 0.98–1.97 1.13 0.84–1.6 0.516
Total memory B cells 3.17 2.23–3.79 2.69 1.88–4.17 2.62 2.24–3.3 0.746
Transitional B cells 0.11 0.05–0.22 0.26 0.18–0.38 0.22 0.14–0.34 0.086
Monocytes (%PBMC)
Classical monocytes 11.85 8.7–13.1 7.81 3.91–15.46 12.11 9.19–16.13 0.215
Intermediate monocytes 0.65 0.53–1.06 0.47 0.28–0.7 0.85 0.53–1.03 0.101
Non-classical monocytes 1.99 a 1.46–2.77 1.18 a,b 0.98–1.64 1.92 b 1.32–2.77 0.003
NK cells (%PBMC)
CD56dimCD16hi NK cells 7.61 4.68–10.5 6.76 3.85–8.21 8.31 6.46–10.35 0.397
CD56dimCD16hiCD57- NK cells 1.91 1.32–2.96 1.68 1.38–2.33 2.03 1.78–3.07 0.436
CD56dimCD16hiCD57+ NK cells 5.46 3.35–7.12 4.63 2.06–5.55 5.51 4.35–6.74 0.568
CD56brightCD16int NK cells 0.32 0.22–0.6 0.33 0.22–0.59 0.38 0.27–0.49 0.885
CD56brightCD16lo NK cells 0.49 0.37–0.62 0.36 0.28–0.61 0.41 0.23–0.55 0.333
DCs (%PBMC)
mDC1 0.44 0.28–0.51 0.32 0.25–0.43 0.36 0.3–0.51 0.428
mDC2 0.03 0.01–0.08 0.06 0.02–0.07 0.06 0.04–0.12 0.094
pDC 0.37 0.33–0.5 0.23 0.17–0.39 0.39 0.33–0.5 0.086
B cells (%B cells)
Antibody secreting cells 0.49 0.27–1 0.52 0.39–1.17 0.67 0.36–1.55 0.598
CD1c− B cells 56.58 a 51.16–66.14 41.63 a 38.86–60.92 53.42 48.75–66.84 0.018
CD1c+ B cells 43.41 a 33.85–48.83 58.36 a 39.07–61.13 46.57 33.15–51.24 0.018
CD24hiCD38−IgD+CD27− B cells 5.82 3.08–9 5.40 3.65–6.85 6.38 4.23–11.68 0.415
CD27− B cells 60.67 56.68–69.43 66.37 60.15–75.44 60.67 56.7–71.89 0.478
CD27+ B cells 37.72 30.02–39.2 32.21 21.33–39.05 29.96 26.77–39.46 0.532
Double negative memory B cells 3.49 2.18–4.58 4.08 3.33–4.67 4.73 3.02–5.89 0.171
Naive B cells 57.66 50.19–62.89 58.68 52.92–66.86 54.05 47.85–66.53 0.588
Non-switched memory B cells 21.18 11.96–24.42 14.67 4.52–19.79 14.11 11.35–22.55 0.316
Switched memory B cells 16.53 11.47–19.89 17.22 14.54–17.62 16.22 13.02–18.88 0.964
Total memory B cells 39.82 34.33–45.48 36.19 25.87–42.64 35.85 30.1–45.16 0.677
Transitional B cells 1.79 a 0.88–2.54 3.20 1.5–4.37 2.75 a 2.47–4.19 0.016
Monocytes (% Monocytes)
All CD16+ monocytes 21.54 17.11–25.82 22.02 13.28–28.39 18.82 16.76–27.1 0.689
Classical monocytes 78.45 74.17–82.88 77.97 71.6–86.71 77.38 71.28–83.23 0.937
Intermediate monocytes 5.68 4.48–7.25 5.54 4.74–7.39 5.48 4.39–7.23 0.962
Non-classical monocytes 15.12 12.19–17.98 10.59 8.23–22.23 11.57 9.34–13.76 0.27
NK cells (% NK cells)
All CD57− NK cells 40.53 34.44–46.76 44.66 34.81–54.67 35.69 27.45–43.83 0.394
All CD57+ NK cells 59.46 52.95–65.44 55.32 45.32–65.18 64.30 56.13–72.53 0.36
CD56dimCD16hi NK cells 85.24 72.69–87.87 81.50 78.06–88.26 87.98 83.56–90.98 0.304
CD56dimCD16hiCD57− NK cells 24.74 15.97–28.89 25.18 19.05–29.44 20.59 17.66–27.44 0.801
CD56dimCD16hiCD57+ NK cells 55.69 48.7–62.41 54.77 43.84–64.84 62.19 53.14–73.11 0.367
CD56brightCD16lo NK cells 5.07 3.95–8.67 5.40 3.52–7.51 3.95 3.09–5.76 0.168
CD56brightCD16int NK cells 5.32 2.26–7.36 4.73 3.38–6.83 3.34 2.88–5.1 0.504
DC (%DC)
All mDC 57.10 49.51–62.99 53.52 43.38–68.46 52.21 46.24–58.39 0.756
mDC1 50.16 40.29–55.09 47.59 30.78–58.68 43.41 37.59–50.22 0.513
mDC2 4.12 a 2.89–7.22 8.57 5.82–9.78 8.79 a 6.56–12.16 0.026
pDC 42.89 37–50.48 46.47 31.53–56.61 47.78 41.6–53.75 0.756
Groups shown were compared using a Kruskal Wallis test; significant results are indicated by bold p values and
shaded background. Letter superscripts indicate groups that were significantly different from each other in post-tests
with Bonferroni’s correction. IQR = interquartile range.
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Appendix B
Table A2. Frequencies of cell subsets in healthy controls, other demyelinating conditions (ODC), early CIS and late CIS analysed by flow cytometry according to the
percentage of total PBMCs, and where relevant, percentage of total B cells, monocytes, NK cells or DCs.
Cell Type Healthy Controls (n = 19) ODC (n = 13)
Early CIS [≤14 Days
Post MRI (n = 6)]
Late CIS [≥27 Days
Post MRI (n = 12)] p Value
Median IQR Median IQR Median IQR Median IQR
%PBMC
γδ-T 0.43 0.28–0.76 0.61 0.23–1 0.36 0.24–0.57 0.43 0.33–0.95 0.845
NKT cells 2.21 1.33–4.1 2.32 1.38–2.72 1.79 1.14–2.49 1.96 1.24–2.66 0.711
Total B cells 8.55 5.71–10.56 7.86 7.06–10.89 6.19 4.87–7.32 8.99 6.71–9.55 0.429
Total DC 0.86 0.68–1.09 0.74 0.51–0.87 0.92 0.71–0.99 0.90 0.78–1.07 0.287
Total monocytes 14.74 10.87–15.71 9.01 5.33–18.1 15.90 11.01–18.46 15.90 11.26–17.93 0.190
Total NK cells 9.59 6.44–11.46 7.72 4.94–9.79 8.91 7.68–10 9.74 7.64–12.16 0.495
B cells (%PBMC)
Antibody secreting cells 0.04 0.02–0.06 0.06 0.03–0.13 0.03 0.03–0.04 0.08 0.02–0.16 0.327
CD1c− B cells 4.43 3.03–6.48 4.26 3.82–5.85 3.15 2.71–4.63 4.78 3.24–5.47 0.628
CD1c+ B cells 2.77 a 2.37–3.68 5.11 a,b 4.06–6.56 3.83 2.82–4.38 2.68 b 2.21–3.38 0.003
CD24hi Naïve B cells 0.35 0.28–0.5 0.50 0.23–0.55 0.53 0.46–0.72 0.46 0.34–0.63 0.376
Double negative memory B cells 0.24 0.15–0.43 0.33 0.23–0.39 0.27 0.22–0.36 0.31 0.2–0.54 0.486
Naïve B cells 4.49 2.58–6.21 4.94 3.81–5.33 2.58 2.56–3.76 5.26 2.88–6.43 0.418
Non-switched memory B cells 1.39 1.06–2.01 0.95 0.5–1.85 1.33 1.08–1.97 1.13 0.91–1.32 0.315
Switched memory B cells 1.08 0.75–1.62 1.34 0.98–1.97 1.26 0.84–1.85 1.11 0.87–1.51 0.714
Total CD27+ B cells 3.00 2.06–3.32 2.37 1.67–3.82 2.58 1.92–3.34 2.11 2.02–2.8 0.742
Total memory B cells 3.17 2.23–3.79 2.69 1.88–4.17 2.87 2.16–3.74 2.62 2.28–3.17 0.871
Transitional B cells 0.11 0.05–0.22 0.26 0.18–0.38 0.13 0.06–0.18 0.26 0.19–0.43 0.036 (post-test NS)
Monocytes (%PBMC)
Classical monocytes 11.85 8.7–13.1 7.81 3.91–15.46 12.25 7.82–17.1 12.11 9.24–15.49 0.378
Intermediate monocytes 0.65 0.53–1.06 0.47 0.28–0.7 0.73 0.45–1.78 0.85 0.61–1 0.188
Non-classical monocytes 1.99 a 1.46–2.77 1.18 a 0.98–1.64 2.26 1.23–2.77 1.92 1.34–2.86 0.009
NK (%PBMC)
CD56dimCD16hi NK cells 7.61 4.68–10.5 6.76 3.85–8.21 7.15 6.04–8.46 8.76 6.77–10.7 0.391
CD56dimCD16hiCD57− NK cells 1.91 1.32–2.96 1.68 1.38–2.33 2.03 1.96–3.07 2.09 1.64–2.87 0.620
CD56dimCD16hiCD57+ NK cells 5.46 3.35–7.12 4.63 2.06–5.55 4.85 3.76–5.81 6.50 4.42–8.73 0.510
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Table A2. Cont.
Cell Type Healthy Controls (n = 19) ODC (n = 13)
Early CIS [≤14 Days
Post MRI (n = 6)]
Late CIS [≥27 Days
Post MRI (n = 12)] p Value
Median IQR Median IQR Median IQR Median IQR
CD56brightCD16int NK cells 0.32 0.22–0.6 0.33 0.22–0.59 0.46 0.4–0.69 0.29 0.23–0.45 0.284
CD56brightCD16lo NK cells 0.49 0.37–0.62 0.36 0.28–0.61 0.59 a 0.46–0.73 0.27 a 0.21–0.41 0.012
DCs (%PBMC)
mDC1 0.44 0.28–0.51 0.32 0.25–0.43 0.30 0.28–0.34 0.43 0.33–0.55 0.283
mDC2 0.03 0.01–0.08 0.06 0.02–0.07 0.05 0.03–0.06 0.09 0.06–0.15 0.073
pDC 0.37 0.33–0.5 0.23 0.17–0.39 0.34 0.31–0.36 0.45 0.36–0.71 0.045 (post-test NS)
B cells (%B cells)
Antibody secreting cells 0.49 0.27–1 0.52 0.39–1.17 0.57 0.36–0.7 0.92 0.29–2.19 0.770
CD1c− B cells 56.58 a 51.16–66.14 41.63 a,b 38.86–60.92 49.46 43.81–51.31 61.17 b 52.77–71.3 0.006
CD1c+ B cells 43.41 a 33.85–48.83 58.36 a,b 39.07–61.13 50.53 48.68–56.18 38.82 b 28.69–47.22 0.006
CD24hi Naïve B cells 5.82 3.08–9 5.40 3.65–6.85 9.50 6.38–13.31 5.66 4.11–10.2 0.338
CD27− B cells 60.67 56.68–69.43 66.37 60.15–75.44 58.04 56.9–62.27 68.60 55.6–73.48 0.413
Double Negative Memory B cells 3.49 2.18–4.58 4.08 3.33–4.67 4.13 3.04–4.98 5.14 2.58–5.96 0.296
Naive B cells 57.66 50.19–62.89 58.68 52.92–66.86 52.05 47.85–55.33 57.84 46.7–66.54 0.585
Non-switched memory B cells 21.18 11.96–24.42 14.67 4.52–19.79 23.92 12.38–26.92 13.04 11.27–17.13 0.147
Switched memory B cells 16.53 11.47–19.89 17.22 14.54–17.62 16.22 14.18–26.17 16.04 11.87–18.32 0.906
Total CD27+ B cells 37.72 30.02–39.2 32.21 21.33–39.05 39.01 36.54–42.13 28.61 24.35–33.44 0.144
Total memory B cells 39.82 34.33–45.48 36.19 25.87–42.64 44.80 40.35–45.25 33.67 29.96–39.25 0.244
Transitional B cells 1.79a 0.88–2.54 3.20 1.5–4.37 2.49 1.32–2.62 4.08 a 2.6–4.87 0.010
Monocytes (% monocytes)
All CD16+ monocytes 21.54 17.11–25.82 22.02 13.28–28.39 19.69 13.35–21.42 18.17 16.89–27.21 0.848
Classical monocytes 78.45 74.17–82.88 77.97 71.6–86.71 77.38 70.83–83.11 77.03 71.33–83.46 0.988
Intermediate monocytes 5.68 4.48–7.25 5.54 4.74–7.39 5.48 4.29–5.93 5.63 4.68–7.24 0.953
Non-classical monocytes 15.12 12.19–17.98 10.59 8.23–22.23 13.76 9.05–15.93 11.32 9.59–12.94 0.435
DC (%DC)
mDC 57.10 49.51–62.99 53.52 43.38–68.46 52.12 50.67–58.05 52.82 44.88–59.06 0.903
mDC1 50.16 40.29–55.09 47.59 30.78–58.68 44.11 40.75–48.26 42.27 37.1–50.34 0.685
mDC2 4.12a 2.89–7.22 8.57 5.82–9.78 7.35 5.81–9.78 10.41 a 6.73–14.96 0.042
pDC 42.89 37–50.48 46.47 31.53–56.61 47.87 41.94–49.32 47.17 40.93–55.11 0.903
NK (%NK)
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Table A2. Cont.
Cell Type Healthy Controls (n = 19) ODC (n = 13)
Early CIS [≤14 Days
Post MRI (n = 6)]
Late CIS [≥27 Days
Post MRI (n = 12)] p Value
Median IQR Median IQR Median IQR Median IQR
All 57− NK cells 40.53 34.44–46.76 44.66 34.81–54.67 42.00 36.08–44.37 31.45 26.17–43.44 0.219
All CD57+ NK cells 59.46 52.95–65.44 55.32 45.32–65.18 57.94 55.62–63.9 68.39 56.51–73.69 0.203
CD56dimCD16hi CD57− NK cells 24.74 15.97–28.89 25.18 19.05–29.44 25.07 18.44–27.44 20.27 17.2–28.29 0.822
CD56dimCD16hi CD57+ NK cells 55.69 48.7–62.41 54.77 43.84–64.84 54.59 42.58–59.48 67.36 57.13–73.44 0.092
CD56dimCD16hi NK cells 85.24 72.69–87.87 81.50 78.06–88.26 80.14 71.69–84.63 89.95 87.13–91.35 0.028 (post-test NS)
CD56brightCD16int NK cells 5.32 2.26–7.36 4.73 3.38–6.83 5.41 2.25–6.98 3.32 2.91–4.17 0.501
CD56brightCD16lo NK cells 5.07 a 3.95–8.67 5.40 3.52–7.51 6.90 b 5.76–7.66 3.33 a,b 2.8–4.65 0.011
Groups shown were compared using a Kruskal Wallis test; significant results are indicated by bold p values and shaded background. Letter superscripts indicate groups that were
significantly different from one other in post-tests with Bonferroni’s correction. IQR = interquartile range; NS = not statistically significant.
Int. J. Mol. Sci. 2017, 18, 1277 16 of 17
References
1. Miller, D.H.; Chard, D.T.; Ciccarelli, O. Clinically isolated syndromes. Lancet Neurol. 2012, 11, 157–169.
[CrossRef]
2. Palanichamy, A.; Apeltsin, L.; Kuo, T.C.; Sirota, M.; Wang, S.; Pitts, S.J.; Sundar, P.D.; Telman, D.; Zhao, L.Z.;
Derstine, M.; et al. Immunoglobulin class-switched B cells form an active immune axis between CNS and
periphery in multiple sclerosis. Sci. Transl. Med. 2014, 6, 248ra106. [CrossRef]
3. Hart, P.H.; Lucas, R.M.; Booth, D.R.; Carroll, W.M.; Nolan, D.; Cole, J.M.; Jones, A.P.; Kermode, A.G.
Narrowband UVB phototherapy for Clinically Isolated Syndrome: A trial to deliver the benefits of vitamin
D and other UVB-induced molecules. Front. Immunol. 2017, 8, 3. [CrossRef]
4. McKay, F.C.; Gatt, P.N.; Fewings, N.; Parnell, G.P.; Schibeci, S.D.; Basuki, M.A.; Powell, J.E.; Goldinger, A.;
Fabis-Pedrini, M.J.; Kermode, A.G.; et al. The low EOMES/TBX21 molecular phenotype in multiple sclerosis
reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies. Clin. Immunol. 2016, 163,
96–107. [CrossRef]
5. Caruana, P.; Lemmert, K.; Ribbons, K.; Lea, R.; Lechner-Scott, J. Natural killer cell subpopulations are
associated with MRI activity in a relapsing-remitting multiple sclerosis patient cohort from Australia.
Mult. Scler. 2016. [CrossRef]
6. Michel, T.; Poli, A.; Cuapio, A.; Briquemont, B.; Iserentant, G.; Ollert, M.; Zimmer, J. Human CD56bright NK
Cells: An Update. J. Immunol. 2016, 196, 2923–2931. [CrossRef]
7. Han, S.; Lin, Y.C.; Wu, T.; Salgado, A.D.; Mexhitaj, I.; Wuest, S.C.; Romm, E.; Ohayon, J.; Goldbach-Mansky, R.;
Vanderver, A.; et al. Comprehensive immunophenotyping of cerebrospinal fluid cells in patients with
neuroimmunological diseases. J. Immunol. 2014, 192, 2551–2563. [CrossRef]
8. Laroni, A.; Armentani, E.; de Rosbo, N.K.; Ivaldi, F.; Marcenaro, E.; Sivori, S.; Gandhi, R.; Weiner, H.L.;
Moretta, A.; Mancardi, G.L.; et al. Dysregulation of regulatory CD56bright NK cells/T cells interactions in
multiple sclerosis. J. Autoimmun. 2016, 72, 8–18. [CrossRef]
9. Mehling, M.; Burgener, A.V.; Brinkmann, V.; Bantug, G.R.; Dimeloe, S.; Hoenger, G.; Kappos, L.; Hess, C.
Tissue distribution dynamics of human NK cells inferred from peripheral blood depletion kinetics after
sphingosine-1-phosphate receptor blockade. Scand. J. Immunol. 2015, 82, 460–466. [CrossRef]
10. Bielecki, B.; Jatczak-Pawlik, I.; Wolinski, P.; Bednarek, A.; Glabinski, A. Central nervous system and
peripheral expression of CCL19, CCL21 and their receptor CCR7 in experimental model of multiple sclerosis.
Arch. Immunol. Ther. Exp. 2015, 63, 367–376. [CrossRef]
11. Krumbholz, M.; Theil, D.; Steinmeyer, F.; Cepok, S.; Hemmer, B.; Hofbauer, M.; Farina, C.; Derfuss, T.;
Junker, A.; Arzberger, T.; et al. CCL19 is constitutively expressed in the CNS, up-regulated in
neuroinflammation, active and also inactive multiple sclerosis lesions. J. Neuroimmunol. 2007, 190, 72–79.
[CrossRef]
12. Rowland, S.L.; Leahy, K.F.; Halverson, R.; Torres, R.M.; Pelanda, R. BAFF-R signaling aids the differentiation
of immature B cells into transitional B cells following tonic BCR signaling. J. Immunol. 2010, 185, 4570–4581.
[CrossRef]
13. Kappos, L.; Hartung, H.P.; Freedman, M.S.; Boyko, A.; Radu, E.W.; Mikol, D.D.; Lamarine, M.; Hyvert, Y.;
Freudensprung, U.; Plitz, T.; et al. Atacicept in multiple sclerosis (ATAMS): A randomised, placebo-controlled,
double-blind, phase 2 trial. Lancet Neurol. 2014, 13, 353–363. [CrossRef]
14. Dooley, J.; Pauwels, I.; Franckaert, D.; Smets, I.; Garcia-Perez, J.E.; Hilven, K.; Danso-Abeam, D.; Terbeek, J.;
Nguyen, A.T.L.; de Muynck, L.; et al. Immunologic profiles of multiple sclerosis treatments reveal shared
early B cell alterations. Neurol. Neuroimmunol. Neuroinflamm. 2016, 3, e240. [CrossRef]
15. Blair, P.A.; Noreña, L.Y.; Flores-Borja, F.; Rawlings, D.J.; Isenberg, D.A.; Ehrenstein, M.R.; Mauri, C.
CD19+CD24hiCD38hi B cells exhibit regulatory capacity in healthy individuals but are functionally impaired
in systemic lupus erythematosus patients. Immunity 2010, 32, 129–140. [CrossRef]
16. Waschbisch, A.; Schröder, S.; Schraudner, D.; Sammet, L.; Weksler, B.; Melms, A.; Pfeifenbring, S.;
Stadelmann, C.; Schwab, S.; Linker, R.A. Pivotal role for CD16+ monocytes in immune surveillance of
the central nervous system. J. Immunol. 2016, 196, 1558–1567. [CrossRef]
17. Fewings, N.L.; Gatt, P.N.; McKay, F.C.; Parnell, G.P.; Schibeci, S.D.; Edwards, J.; Basuki, M.A.; Goldinger, A.;
Fabis-Pedrini, M.J.; Kermode, A.G.; et al. The autoimmune risk gene ZMIZ1 is a vitamin D responsive
marker of a molecular phenotype of multiple sclerosis. J. Autoimmun. 2017, 78, 57–69. [CrossRef]
Int. J. Mol. Sci. 2017, 18, 1277 17 of 17
18. Chuluundorj, D.; Harding, S.A.; Abernethy, D.; La Flamme, A.C. Expansion and preferential activation of the
CD14+CD16+ monocyte subset during multiple sclerosis. Immunol. Cell Biol. 2014, 92, 509–517. [CrossRef]
19. Chuluundorj, D.; Harding, S.A.; Abernethy, D.; La Flamme, A.C. Glatiramer acetate treatment normalized
the monocyte activation profile in MS patients to that of healthy controls. Immunol. Cell Biol. 2017, 95,
297–305. [CrossRef]
20. Mansour, S.; Tocheva, A.S.; Cave-Ayland, C.; Machelett, M.M.; Sander, B.; Lissin, N.M.; Molloy, P.E.;
Baird, M.S.; Stubs, G.; Schroder, N.W.; et al. Cholesteryl esters stabilize human CD1c conformations for
recognition by self-reactive T cells. Proc. Natl. Acad. Sci. USA 2016, 113, E1266–E1275. [CrossRef]
21. Longhini, A.L.F.; von Glehn, F.; Brandão, C.O.; de Paula, R.F.; Pradella, F.; Moraes, A.S.; Oliveira, E.C.;
Quispe-Cabanillas, J.G.; Abreu, C.H.; et al. Plasmacytoid dendritic cells are increased in cerebrospinal fluid
of untreated patients during multiple sclerosis relapse. J. Neuroinflamm. 2011, 8, 2. [CrossRef]
22. Polman, C.H.; Reingold, S.C.; Banwell, B.; Clanet, M.; Cohen, J.A.; Filippi, M.; Fujihara, K.; Havrdova, E.;
Hutchinson, M.; Kappos, L.; et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald
criteria. Ann. Neurol. 2011, 69, 292–302. [CrossRef]
23. Ziegler-Heitbrock, L.; Ancuta, P.; Crowe, S.; Dalod, M.; Grau, V.; Hart, D.N.; Leenen, P.J.M.; Liu, Y.-J.;
MacPherson, G.; Randolph, G.J.; et al. Nomenclature of monocytes and dendritic cells in blood. Blood 2010,
116, e74–e80. [CrossRef]
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
